Knowledge Library

Ketamine – The Next Breakthrough for Depression?

A Modern Epidemic Major Depressive Disorder (MDD) affects an estimated 320 million individuals worldwide (16 million in the U.S. alone), and the incidence of this condition has increased substantially in the last decade. Further challenging psychiatrists, current pharmacologic therapies (MAO inhibitors, tricyclic antidepressants, and SSRIs) are limited by therapeutic lag times of up to weeks or months, and high refractory rates of approximately 30%. Patients with treatment-resistant depression face limited options, such as transcranial magnetic stimulation (r-TMS) or electroconvulsive therapy (ECT), and patients with suicidal ideation may remain at risk while they wait for a newly-prescribed antidepressant to take effect....

Read More ยป Filed under: ,